Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00933270 · ClinicalTrials.gov registry record · NA

Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery

A NA study, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
325
Enrollment target

NCT00933270 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 325 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00933270, a NA study, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
325 participants
Enrollment target

Study Summary

This is a prospective, multicenter, non-randomized, single arm, pivotal trial. The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA® Nitinol Stent System in treating subjects with obstructive superficial femoral artery (SFA) disease. The primary endpoint will be the primary patency of the SFA evaluated at 12 months. The outcome will be compared to a performance goal based on clinical trials of percutaneous transvenous angioplasty (PTA) alone.

Interventions

  • DEVICE SUPERA® Nitinol Stent System

Trial Details

FieldValue
Enrollment Target 325 participants
Start Date 2009-07
Est. Completion 2014-07
Phase NA

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT00933270

The ClinicalTrials.gov registry entry for NCT00933270 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SUPERA® Nitinol Stent System is the first listed.

NCT00933270 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00933270 about?

NCT00933270 is a clinical study titled "Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery". This is a prospective, multicenter, non-randomized, single arm, pivotal trial. The main objective of this study is to demonstrate the safety and effectiveness of the IDev SUPERA® Nitinol Stent System in treating subjects with obstructive superficial femoral artery (SFA) disease. The primary endpoin...

What is the current status of trial NCT00933270?

This trial is currently completed. It is a NA study. The enrollment target is 325 participants. The study started on 2009-07. Estimated completion is 2014-07.

What interventions are being tested in trial NCT00933270?

The interventions under investigation include: SUPERA® Nitinol Stent System (DEVICE).

Who is sponsoring clinical trial NCT00933270?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.